Fennec Pharmaceuticals Inc (FENC)

$FENC Current Stock Price: $8.72 Contracts to trade: $10.0 FENC Mar 20 2026 Call Entry: $0.45 Exit: $0.72 ROI: 61% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$FENC (+2.1% pre) Fennec presents real world data on PEDMARK for head and neck cancer patients https://ooc.bz/l/94023

$FENC Fennec Pharmaceuticals commercializes PEDMARK for pediatric oncology, facing single-product concentration and royalty-based revenue model

$FENC Fennec PharmaceuticalsInc. (NASDAQ: FENC) was started with a Buy rating at B. Riley with a $16 target price.

$FENC $7.90 bid. Holding long position https://stocktwits.com/G101SPM/message/603287700 BRIEF: Fennec Pharmaceuticals (FENC) initiated with a Buy at B. Riley, tgt $16

$FENC Fennec Pharmaceuticals; biotech (pediatric oncology); commercial-stage; royalty-based model, but single product concentration risk.

$FENC Market balancing opposing forces

$FENC 2026 will be the breakthrough year in regard or revenue and net profit. This year will change everything and it´s is just the beginning of a several years upwards move!

$FENC possible worst management team ever

$FENC RSI: 44.78, MACD: -0.0696 Vol: 0.14, MA20: 7.64, MA50: 7.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$FENC Current Stock Price: $7.87 Contracts to trade: $7.5 FENC Jan 16 2026 Call Entry: $0.50 Exit: $0.94 ROI: 90% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$FENC Investors are watching management behavior more closely than guidance language. Execution gaps should narrow meaningfully. Operational wins could gradually shift expectations upward. Credibility grows when performance becomes repeatable.

$FENC Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Sequential improvement must start appearing across core metrics. A series of confirmed wins might reduce the required risk premium. Execution precision will determine whether this evolves or stalls.

$FENC Share Price: $7.64 Contract Selected: May 15, 2026 $10 Calls Buy Zone: $0.50 – $0.61 Target Zone: $0.85 – $1.04 Potential Upside: 62% ROI Time to Expiration: 148 Days | Updates via https://fxcapta.com/stockinfo/

Commercial-stage oncology focused M&A has been active with 6 acquisitions YTD (still 3.5 weeks left), 4 in FY24 & 5 in FY23. They are averaging more than 1 per quarter (right side of the attachment). In May 24 MACK was technically an exit but via CVR payout so after Ono acquired DCPH in April via traditional M&A, there was a 10 month dry spell. Our investment club believes there will be an acquisition before JP Morgan, most likely SNDX by INCY. We're speculating so of course we c/b wrong. The left side of the attachment lists all available & reasonably credible candidates. $KPTI is a textbook example of why bios should exit after FDA approval. Of course KPTI may work out with 2 major reads next year (they know it works in endometrial). Because they've waited this long we believe there's no chance they sell but again o/c we c/b wrong. Same with $FENC but at least they tried Our other most likely candidates include (in order) $URGN & $ZYME $DCTH by March (3 years since the P/E financing)

$FENC The STS-J01 study in Japan shows PEDMARK dramatically reduces pediatric hearing loss from typical 56–63% levels to only 24%. See why investors believe Fennec Pharmaceuticals could be at the start of a major international growth cycle. https://biotechhealthx.com/biotech-news/fennec-pharmaceuticals-fenc-reveals-stunning-japan-trial-data-hearing-loss-drops-from-63-to-just-24/

$FENC management so bad! RuNNN fast.

$FENC (+1.6% pre) Fennec reports positive Japan trial results for PEDMARK hearing loss drug https://ooc.bz/l/85923

Big win for $FENC — latest topline shows strong momentum as PEDMARK® sales surge, cash flow turns positive, and global expansion (EU + Japan) gains traction 🌍💊. With orphan-drug protection and rising adoption, Fennec looks well-positioned for growth. #biotech #pharma #stocks

$FENC $8.00 +0.27. Holding long position/maintain EXIT https://stocktwits.com/search/u/G101SPM?symbol=FENC BRIEF: Co announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan. PEDMARK® is the first and only U.S. Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors. The study, which enrolled 27 patients in the primary cohort (patients aged 3-18 years) and 6 in exploratory cohorts and examined the addition of PEDMARK® administered six hours after cisplatin. The primary endpoint of the study was met and the data showed that 24% and 16% of evaluable patients who were treated with PEDMARK® experienced hearing loss (ototoxicity) as assessed by the American Speech Language-Hearing Association criteria and Brock grade scaling, respectively. These rates compare favorably to the cisplatin-only arms of PEDMARK®'s pivotal Phase 3 trials, where 56% of children developed clinically significant hearing loss using ASHA criteria (ACCL0431) and 63% developed hearing impairment defined as Brock Grade =1 (SIOPEL-6). Further, the study demonstrated that among the largest subgroup of patients aged 7--18 years, hearing loss occurred in only 19% (ASHA) and 14.3% (Brock).

$FENC https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ On this week's AI catyst scanner result

A follow up around the $DCTH share buyback. Attached is a comparison to peer $FENC (peer in the sense they have roughly the same market cap). Note DCTH trades at a much lower revenue multiple (actual & projected) while having a much lower enterprise value. This is not to bash FENC. PedMark is a life-changing therapy. We are only pointing out the differences in valuation relative to revenues. $XBI $IBB $NBI